3 Stocks With Jaw-Dropping Growth Potential

MiMedx, The Medicines Company, and Pacira Therapeutics should all see huge leaps in their earnings going forward. Here's what you need to know.

Jul 18, 2014 at 5:03PM

The biopharma industry has exploded with new public companies over the last two years. As a result, it's become all too easy to miss promising companies that offer stellar growth prospects going forward. 

MiMedx (NASDAQ:MDXG)The Medicines Company (NASDAQ:MDCO), and Pacira Therapeutics (NASDAQ:PCRX) are three biopharma stocks that offer impressive potential worth a deeper look.

MDXG Chart

MDXG data by YCharts

MiMedx is seeing impressive demand for its wound-healing technologies
MiMedx is a small-cap biopharma that develops wound healing technologies from human amniotic membranes, taken from donated placentas. The company's product portfolio includes AmnioFix for surgical procedures and EpiFix for chronic and surgical-based wounds.

Earlier this year, MiMedx increased the lower bound of its 2014 annual guidance, which now ranges from $105 to $110 million. If this guidance holds, it means that MiMedx shares are presently trading at roughly seven times projected 2014 revenues. With earnings expected to show up next year to the tune of 16 cents per share according to Capital IQ, MiMedx shares are starting to look interesting to me.

That being said, shorts have built a large position in this stock, suggesting that this growth story may have some holes. Shorts have targeted MiMedx for three reasons: a SEC investigation into the CEO that was recently dismissed, payer issues that may slow the market uptake of its technologies, and a bearish forecast over the commercial opportunity for AmnioFix and EpiFix.

My view is that the trend speaks for itself. MiMedx has 3 years of rapidly increasing sales on its side and the SEC investigation was never a threat to the company, only the CEO for his actions in a prior position. At the end of the day, MiMedx is gaining ground in an exciting space, making it a stock to watch.

The Medicines Company is well positioned for growth
The Medicines Company sports a diversified product pipeline headlined by Angiomax, a potent blood-thinner used primarily in heart-related procedures. Angiomax saw sales increase by 9% year over year in the first quarter of 2014, raking in $155.7 million. The drug is under some potential generic threat after an unfavorable court ruling, so it's important to watch legal issues closely with this company given that Angiomax represents 88% of the company's overall revenue.

Although Angiomax has seen impressive growth, there is a lot more to this company worth checking out. In particular, The Medicines Company has a handful of registrational stage products either under review or nearing a review with the Food and Drug Administration.

One I'd like to highlight is Fibrocaps, a dry powder formulation that is used to stop excessive bleeding in surgery when other means are ineffective. The drug's Biologic License Application is set to be reviewed by Jan. 31, 2015, and the company estimates peak sales at around $300 million per year. Of course, it hasn't all been sunshine and daisies for the company -- Cangrelor, its anticoagulant with peak sales of around $400 million, was rejected by the FDA in April of this year.

The Medicines Company bottom line is rebounding as more clinical-stage products move into the commercial phase of their life cycle. I'm looking to see strong levels of growth in terms of earnings and revenues from this mid-cap biopharma over the next year.

Pacira Therapeutics' growth has been fueled by Exparel
Shares of Pacira Therapeutics have blasted northward over the last year by 140% based on growing sales for its nonopioid postsurgical pain analgesic Exparel. Presently, the drug is commonly being prescribed for postoperative pain in procedures like bunionectomy and hemorrhoidectomy. 

But the company is planning on expanding its use in the coming years to include a potential nerve-block indication, with global peak sales estimates north of $500 million per year, if its label can be successfully expanded. That being said, I'm concerned Pacira's market cap of $3 billion has baked in a lot of the explosive top line growth that would come from this potential expanded use for Exparel.

Foolish wrap-up
The biopharma industry is rich with compelling growth stories at the moment, driven by new approvals and improving clinical trial designs. Among the three growth stocks discussed above, Pacira's story is the only one that seems to have garnered much attention among investors thus far, evidenced by the strong appreciation of its share price. Nonetheless, I think investors should definitely dig deeper into MiMedx and The Medicines Company, which appear to offer decent upside potential with manageable risk profiles going forward. That said, biotech is inherently a risky area to invest -- any number of things could prevent this epic growth from being realized (including failing to get FDA approval and a weak drug launch) -- so be careful when considering these high-risk/high-reward opportunities.

Jaw-dropping growth potential for your portfolio
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers